Publication | Closed Access

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

Diabetes ManagementInsulin-naive PatientsInsulin ManagementDiabetesType 2Clinical TrialsDiabetes MellitusInsulin Degludec ThreeInsulin DeliveryMedicine